Business
Optimer-Fc launched for immunohistochemistry
Optimer-Fc launched for immunohistochemistry.
About this update from Aptamer Group Plc
[{"type":"text","content":"\n \n \n \n 20 March 2023\n \n \n \n \n \n \n \n \n \n Aptamer Group plc\n \n \n \n \n (\"Aptamer\", or \" the Group\")\n \n \n \n \n \n \n \n \n \n Aptamer launches Optimer®-Fc as a new reagent solution for immunohistochemistry\n \n \n \n \n \n \n \n \n - Existing pipeline of IHC work including potential trials with Optimer®-Fc with two top 10 pharma companies\n \n \n - Aptamer is currently working with one of the top three IHC company to validate the Optimer-Fc platform\n \n \n - IHC Optimer binders are being developed for several other pharma and biotech customers\n \n \n \n \n \n \n \n Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, announces that it has developed a new reagent, Optimer®-Fc, for use in automated immunohistochemistry (IHC) workflows.\n \n \n Aptamer is working with one of the top three companies within the IHC market (that jointly command over 70% of the market) to validate the performance of Optimer-Fc within their automated IHC platform and is in current negotiations with two top 10 pharmaceutical companies seeking to trial Optimer-Fc. Aptamer is also currently working with four of the top ten pharma companies and additional biotech partners to develop Optimer binders for IHC - a deep pipeline of potential future products to advance research and diagnostics for the benefits of life science.\n \n \n IHC remains the gold standard test for clinical diagnostics (including cancer), and its use is increasing with the advent of personalised medicine approaches. The IHC market was valued at $2.3BN in 2021, with 45.5% accounted for by the antibody segment. However, the imminent expiry of current patents for IHC antibodies is a significant challenge facing the major players in this field, with an expected decrease in revenue and profitability. Innovative products, such as Optimer-Fc, are actively being sought to overcome these issues.\n \n \n Optimer-Fc tools consist of an Optimer binder conjugated to the Fc domain of an antibody. The Company has successfully demonstrated the functional integration of different Optimer binders into this conjugate format. This allows the broad target range of Optimer tools to be applied in IHC applications.\n IHC is a staining process predominantly done o...